

CITATION REPORT

List of articles citing

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects

DOI: 10.1177/0091270008315315

Journal of Clinical Pharmacology, 2008, 48, 610-8.

Source: <https://exaly.com/paper-pdf/43847768/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
90	Safety and tolerability of bosentan in the management of pulmonary arterial hypertension. <i>Drug Design, Development and Therapy</i> , 2009 , 3, 111-8	4.4	1
89	Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. <i>Vascular Health and Risk Management</i> , 2009 , 5, 607-19	4.4	24
88	Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. <i>Pharmacology & Therapeutics</i> , 2009 , 122, 216-38	13.9	273
87	Non-congenital heart disease associated pediatric pulmonary arterial hypertension. <i>Progress in Pediatric Cardiology</i> , 2009 , 27, 13-23	0.4	18
86	No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. <i>Journal of Pharmaceutical Sciences</i> , 2009 , 98, 4962-74	3.9	52
85	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. <i>Advances in Therapy</i> , 2009 , 26, 813-25	4.1	75
84	Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors--assembling the clues. <i>British Journal of Clinical Pharmacology</i> , 2009 , 67, 475-7	3.8	2
83	Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>European Heart Journal</i> , 2009 , 30, 2493-537	9.5	2531
82	Updated evidence-based treatment algorithm in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2009 , 54, S78-S84	15.1	379
81	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009 , 62, 1464.e1-1464.e58	0.7	1
80	Tadalafil therapy for pulmonary arterial hypertension. <i>Circulation</i> , 2009 , 119, 2894-903	16.7	769
79	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia</i> , 2009 , 62, 1464.e1-1464.e58	1.5	3
78	Pharmacotherapeutic management of pulmonary arterial hypertension. <i>Cardiology in Review</i> , 2010 , 18, 148-62	3.2	47
77	Pharmacologic and pharmacokinetic rationale for combination therapy in pulmonary arterial hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2010 , 56, 686-95	3.1	3
76	Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. <i>Antiviral Therapy</i> , 2010 , 15, 157-63	1.6	33
75	The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. <i>Vascular Health and Risk Management</i> , 2010 , 6, 273-80	4.4	21
74	Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. <i>Drug Design, Development and Therapy</i> , 2010 , 4, 61-70	4.4	28

73	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 127-32	4	27
72	Bosentan. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1023-34	4	6
71	Tadalafil: in pulmonary arterial hypertension. <i>Drugs</i> , 2010 , 70, 479-88	12.1	12
70	Targeted oral therapies in the treatment of pulmonary arterial hypertension. <i>Clinical Drug Investigation</i> , 2010 , 30, 811-826	3.2	11
69	Antihypertensive drugs. <i>Side Effects of Drugs Annual</i> , 2010 , 375-400	0.2	
68	Emerging drugs for pulmonary hypertension. <i>Expert Opinion on Emerging Drugs</i> , 2010 , 15, 71-85	3.7	11
67	Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension. <i>Current Medical Research and Opinion</i> , 2011 , 27, 1827-34	2.5	11
66	Tadalafil. <i>Profiles of Drug Substances, Excipients and Related Methodology</i> , 2011 , 36, 287-329	3	13
65	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2011 , 30, 632-43	5.8	79
64	Treatment of pulmonary hypertension: bench to bedside. <i>Respiratory Medicine</i> , 2011 , 105 Suppl 1, S7-11	4.6	1
63	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2011 , 5, 315-28	3.8	7
62	Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. <i>Clinical Therapeutics</i> , 2011 , 33, 993-1004	3.5	27
61	Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. <i>European Journal of Pharmacology</i> , 2011 , 660, 298-304	5.3	30
60	Bosentan for the treatment of adult pulmonary hypertension. <i>Future Cardiology</i> , 2011 , 7, 19-37	1.3	9
59	Risk assessment of mechanism-based inactivation in drug-drug interactions. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 1653-7	4	11
58	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 1784-805	2.9	54
57	The pharmacological treatment of pulmonary arterial hypertension. <i>Pharmacological Reviews</i> , 2012 , 64, 583-620	22.5	88
56	Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. <i>Respiratory Medicine</i> , 2012 , 106, 730-4	4.6	20

55	Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertension. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 990-8	3.8	4
54	Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension. <i>Journal of Cardiology</i> , 2012 , 60, 344-9	3	21
53	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 747-55	4	13
52	Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction. <i>Drugs and Aging</i> , 2012 , 29, 771-81	4.7	8
51	ADMET considerations for phosphodiesterase-5 inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 1231-45	5.5	12
50	Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. <i>Pediatric Pulmonology</i> , 2013 , 48, 27-34	3.5	67
49	High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 197-207	2.8	6
48	Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors. <i>Pediatric Cardiology</i> , 2013 , 34, 213-9	2.1	9
47	Simple and sensitive liquid chromatography-tandem mass spectrometry methods for quantification of tadalafil in rat plasma: application to pharmacokinetic study in rats. <i>Archives of Pharmacal Research</i> , 2013 , 36, 457-63	6.1	8
46	Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. <i>Biochemical Pharmacology</i> , 2013 , 85, 265-73	6	39
45	Endothelin receptor antagonists for pulmonary arterial hypertension. <i>The Cochrane Library</i> , 2013 , CD004434	4.2	28
44	Combination therapy in pulmonary arterial hypertension. <i>Clinics in Chest Medicine</i> , 2013 , 34, 841-55	5.3	11
43	Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2013 , 7, 39-49	4.9	13
42	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. <i>Global Cardiology Science & Practice</i> , 2014 , 2014, 257-90	0.7	10
41	Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 576-83	3.2	14
40	Drug treatment of pulmonary hypertension in children. <i>Paediatric Drugs</i> , 2014 , 16, 43-65	4.2	32
39	Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 550-7	2.6	10
38	Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. <i>Hypertension Research</i> , 2014 , 37, 507-12	4.7	38

37	Pharmacological Treatment of Pulmonary Hypertension. 2014 , 375-431		
36	Medical treatment for an adult patient with Eisenmenger syndrome. A case report. <i>International Heart Journal</i> , 2015 , 56 Suppl, S8-11	1.8	2
35	Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. <i>Core Evidence</i> , 2015 , 10, 99-109	4.9	19
34	Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. <i>BMC Pulmonary Medicine</i> , 2015 , 15, 62	3.5	3
33	Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 437-49	5.5	20
32	Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension. <i>Pediatric Critical Care Medicine</i> , 2016 , 17, S89-100	3	11
31	Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , 2016 , 102 Suppl 2, ii67-85	5.1	43
30	Bosentan. 2016 , 1033-1036		
29	A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. <i>Neurology</i> , 2017 , 89, 1811-1820	6.5	42
28	Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension: a sub-group analysis based on Japan post-marketing surveillance. <i>Current Medical Research and Opinion</i> , 2017 , 33, 2241-2249	2.5	12
27	Drug-drug interactions of cytostatics with regular medicines in lung cancer patients. <i>Journal of Oncology Pharmacy Practice</i> , 2017 , 23, 483-490	1.7	4
26	Metabolism and Disposition of a Novel Selective 7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 122-130	4	4
25	Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending-dose study. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2302-2309	3.8	5
24	2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 1584-1609	3.2	11
23	Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2019 , 13, 1753-1766	4.9	7
22	The burden of comorbidities in pulmonary arterial hypertension. <i>European Heart Journal Supplements</i> , 2019 , 21, K21-K28	1.5	19
21	Oral drugs used to treat persistent pulmonary hypertension of the newborn. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 1295-1308	3.8	3
20	Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 915-930	2.9	19

19	Drug Treatment of Pulmonary Hypertension in Children. <i>Paediatric Drugs</i> , 2020 , 22, 123-147	4.2	7
18	Endothelin receptor antagonists for pulmonary arterial hypertension. <i>The Cochrane Library</i> , 2021 , 3, CD014434	0.2	1
17	Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	2
16	[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. <i>Archivos De Cardiologia De Mexico</i> , 2015 , 85, 215-24	0.2	6
15	The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension. <i>International Heart Journal</i> , 2020 , 61, 799-805	1.8	2
14	Long term combination treatment for severe idiopathic pulmonary arterial hypertension. <i>World Journal of Cardiology</i> , 2010 , 2, 68-70	2.1	3
13	Bioequivalence and food effect of a fixed-dose combination of macitentan and tadalafil: Adaptive design in the COVID-19 pandemic. <i>Pharmacology Research and Perspectives</i> , 2021 , 9, e00846	3.1	1
12	Pulmonary Arterial Hypertension. 2010 , 195-211		
11	The Real World of Medical Treatment of Pulmonary Arterial Hypertension—Small Evidence, but Heavy Cornerstone— <i>Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery</i> , 2015 , 31, 157-183	0	
10	Drug interactions in urology - what to watch out for. <i>Urologie Pro Praxi</i> , 2020 , 21, 80-86	0.1	0
9	A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension. <i>Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery</i> , 2010 , 26, 206-218	0	1
8	2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension. <i>Acta Cardiologica Sinica</i> , 2014 , 30, 401-44	1.1	11
7	Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 ,	4.5	1
6	Safety and Tolerability of Combination Therapy with Ambrisentan and Tadalafil for the Treatment of Pulmonary Arterial Hypertension in Children: Real-World Experience.. <i>Pediatric Pulmonology</i> , 2021 ,	3.5	1
5	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879		18
4	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.		58
3	Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension. 875512252211140		0
2	Development of a Rapid LC-MS/MS Method for Simultaneous Quantification of Donepezil and Tadalafil in Rat Plasma: Its Application in a Pharmacokinetic Interaction Study after Oral Administration in Rats. 2023 , 28, 2352		0

1 Bosentan effect on Teneligliptin Antidiabetic effect in Animal Model. **2023**, 550-554

o